The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Nektar Therapeutics shares valued at $137,946 were purchased by Zalevsky Jonathan on Jan 20 ’26. At $35.67 per share, Zalevsky Jonathan acquired 3,867 shares.
Also, Zalevsky Jonathan sold 1,157 shares, netting a total of over 62,802 in proceeds. Following the sale of shares at $54.28 each, the insider now holds 18,971 shares.
Before that, Wilson Mark Andrew had sold 630 shares from its account. In a trade valued at $34,196, the Chief Legal Officer traded Nektar Therapeutics shares for $54.28 each. Upon closing the transaction, the insider’s holdings decreased to 630 shares, worth approximately $0.8 million.
As published in their initiating research note from Citigroup on November 26, 2025, Nektar Therapeutics [NKTR] has been a Buy and the price target has been revised to $102. Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in late June. As of June 24, 2025, BTIG Research has reiterated its “Buy” rating for NKTR. Earlier on April 11, 2025, Jefferies upgraded its rating. Their new recommendation was “a Buy” for NKTR stock which previously was a “a Hold”.
Analyzing NKTR Stock Performance
On last trading session, Nektar Therapeutics [NASDAQ: NKTR] rose 1.90% to $36.92. The stock’s lowest price that day was $35.1, but it reached a high of $36.99 in the same session. During the last five days, there has been a surge of approximately 0.93%. Over the course of the year, Nektar Therapeutics shares have jumped approximately 175.93%.
Is Nektar Therapeutics subject to short interest?
Stocks of Nektar Therapeutics saw a sharp rise in short interest on 2025-12-31 jumping by 1.12 million shares to 2.94 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 1.82 million shares. A jump of 38.04% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.07 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.07.
Which companies own the most shares of Nektar Therapeutics (NKTR)?
In terms of Nektar Therapeutics share price expectations, FactSet research, analysts set an average price target of 121 in the next 12 months, up nearly 233.98% from the previous closing price of $36.23. Analysts anticipate Nektar Therapeutics stock to reach 135 by 2026, with the lowest price target being 115. In spite of this, 3 analysts ranked Nektar Therapeutics stock as Buy at the end of 2026. On March 14, 2025, Oppenheimer assigned a price target of “an Outperform” to the stock and upgraded coverage with a $6.
